CA2226523A1 - A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions - Google Patents

A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions Download PDF

Info

Publication number
CA2226523A1
CA2226523A1 CA002226523A CA2226523A CA2226523A1 CA 2226523 A1 CA2226523 A1 CA 2226523A1 CA 002226523 A CA002226523 A CA 002226523A CA 2226523 A CA2226523 A CA 2226523A CA 2226523 A1 CA2226523 A1 CA 2226523A1
Authority
CA
Canada
Prior art keywords
growth hormone
zinc
formulation
optionally
calcium ions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002226523A
Other languages
French (fr)
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmegaard Sorensen
Ole Hvilsted Olsen
Lars Thim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2226523A1 publication Critical patent/CA2226523A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

A pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.

Description

CA 02226~23 1998-01-08 TITLE

A ST~Rn ~ n PHARM~CEUTICAL PORMULATI~N COMII'RISING A GROWTH HORMONE
PRE-lREATED WITH ZINC AND OPI'IONALLY LYSINE OR CALCIUM IONS

The present invention relates to a stabilized pharmaceutical formulation comprising growth hormone, to a method of making such formulation, to the use of zinc for stabilizing a for-mulation of growth hormone, and to a method for treating adisorder affectable by growth hormone.

BACKGROUND OF THE INVENTION

The growth hormones from man and from the common domestic ~nim~l S are proteins of approximately l91 amino acids, syn-thesized and secreted from the anterior lope of the pitui-tary gland. Human growth hormone consists of 191 amino acids.
Growth hormone is a key hormone involved in the regulation of not only somatic growth, but also in the regulation of metabolism of proteins, carbohydrates and lipids. The ma]or effect of growth hormone is to promote growth.
The organ systems affected by growth hormone include the skeleton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys.

Until the development of the recombinant technology and the cloning of the growth hormone gene now giving rise to production of e.g. human growth hormone (hGH) and Met-hGH in industrial scale, human growth hormone could only be obtained by extraction from the pituitary glands of human cadavers. The very limited supplies of growth hormone restricted the use thereof to longitudinal growth promotion in childhood and puberty for treatment of dwarfism, even CA 02226~23 1998-01-08 W097/03692 PCT~K96/00293 though it has been proposed for inter alia treatment of short stature (due to growth hormone deficiency, normal short stature and Turner syndrome), growth hormone deficiency in adults, infertility, treatment of burns, wound healing, dystrophy, bone knitting, osteoporosis, diffuse ga-stric bleeding, and pseudoarthrosis.

Furthermore, growth hormone has been proposed for increasing the rate of growth of domestic ~nim~1s or for decreasing the proportion of fat in ~nim~ls to be slaughtered for human consumption.

Pharmaceutical formulations of growth hormone tend to be un-stable. Degradation products such as deamidated or sulfoxy-dated products and dimer or polymer forms are generated -especially in solutions of growth hormone.

The pre~om;n~nt degradation reactions of hGH are 1) deamida-tion by direct hydrolysis or via a cyclic succinimide intermediate to form various amounts of L-asp-hGH, L-iso-asp-hGH, D-asp-hGH, and D-iso-asp-hGH (ref 1-3), and 2) oxidation of the methionine residues in positions 14 and 125 (ref 4-9). The major degradation product of hGH in lyophilized state as well as in solution is deamidated hGH.
Deamidation especially takes place at the Asn in position 149 and to a minor extent in position 152.

hGH is also rather easily oxidized in positions 14 and 125.
The oxidation of hGH in solution forming sulfoxides is nor-mally due to the oxygen dissolved in the formulation. The solubility of oxygen in distilled water is about 200 ~M (9).
As the concentration of hGH in a formulation comprising 4 IU/ml is 1.3 mg/ml corresponding to 60nM hGH, oxygen will, at normal storing conditions, be present in an excess of about 3000 times the stoichiometric amount for oxidation of CA 02226~23 l998-0l-08 W097/03692 PCT~K96/00293 hGH. It is not feasible to try to solve the problem by degassing of buffers before tapping and packing the formulations.

At present, it is not believed that these deamidated forms and oxidized forms of hGH should have toxic or altered biological activity or receptor binding properties, but there is indication to the effect that the conformation stability of the sulfoxides is reduced as compared to native hGH.

For the development of a stable, dissolved formulation com-prising hGH it is of importance to know the rate of deamida-tion and formation of sulfoxides as well as means to control the reactions.

The kinetics of degradation depend on temperature, pH and various additives or adjuvants in the hGH formulation.

Due to the instability, growth hormone is, at present, lyophilized and stored in the lyophilized form at 4~C until it is reconstituted for use in order to m;n;m; ze the degradation.

The lyophilized pharmaceutical formulations comprising hGH
are, at present, reconstituted by the patient and then stored as a solution during the use for a period of up to 14 days at 4~C, during which some degradation will take place.

Furthermore, the process of reconstitution of the lyophilized growth hormone tends to provide difficulties for the patient.

Thus, it is at present preferred to reconstitute the growth hormone as late as possible before use and to store and ship the formulation in a lyophilized state. The chain from the CA 02226~23 1998-01-08 W097/03692 PCT~K96/00293 manufacturer to the pharmacy is apt for handling the formulations at a controlled low temperature of e.g. 4~C
which allows for a long shelf life of up to two years.

However, the extended use of pen systems for self-medication and the expanded field of use calls for a formulation which is stable for a sufficient long time with the end user under conditions where "sufficient" cooling is not always avai-lable.
Preferably, a formulation should be stable with the end user in a lyophilized state for about one month and additionally for one month in a reconstituted state in a pen device for the intended period of use of a cartridge.
Thus, there is a need for more stable formulations of growth hormone being stable in a lyophilized state at a relative high temperature for a period and additionally for a period of use at a relatively high temperature in solution. Such stabilization is of very great importance when moving the administration of the growth hormone from clinics to the ho-mes of the individuals to be treated where optimal storage may not be available as indicated above.

Furthermore, the shift in pattern of administration of growth hormone to the use of pen devices calls for a stable dissolved formulation comprising growth hormone in order to facilitate the handling to be performed by the patient. A
stable dissolved formulation comprising growth hormone may be produced ready to use in the form of cartridges fitting into the pen device used by the patient who may then avoid the reconstitution of the formulation and, hence, will not have to be in the possession of a lyophilized formulation, a suitable vehicle for reconstitution as well as the necessary skill and sterile equipment for sterile reconstitution of the formulation.

CA 02226~23 l998-0l-08 W097/03692 PCT~K96/00293 For safety reasons it will also be desirable to avoid the reconstitution of a lyophilized ~ormulation just before the use of the formulation.
Furthermore, it would also be an advantage to avoid the lyo-philization step in the production of growth hormone formulations. Lyophilization is a time consuming and costly process and is also often a "bottleneck" in the production due to the limited capacity of the freeze drier.

Thus, there is a need to reduce the rate of the degradation processes in order to allow for dissolved hGH formulations being stable during shelf life and during the period of use of up to one month.

Prior attempts to stabilize hGH has not fully succeeded in preventing the formation of dimer. The problems associated with dimer formation is e.g noted in Becker, G.W., Biotech-nology and Applied Biochemistry 9, 478 (1987).

International Patent Publication No. WO 89/09614 and Austra-lian patent application No. 30771/89 disclose a stable phar-maceutical formulation containing human growth hormone, gly-cine, and mannitol. Such a formulation shows improved stabi-lity during normal processing and storage in a lyophilized state as well as in the period of use after the reconstitu-tion.

Published European patent application No. 303 746 discloses that ~nim~l growth hormone may be stabilized with various stabilizers to give decreased formation of insolubles and preservation of the soluble activity in aqueous ~ environments, such stabilizers including certain polyols, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts. Polyols are selected from the group consisting of non-reducing sugars, CA 02226~23 l998-0l-08 W097/03692 PCT~K96/00293 sugar alcohols, sugar acids, pentaerythritol, lactose, water-soluble dextrans and Ficoll; amino acids are selected from the group consisting of glycine, sarcosine, lysine or salts thereof, serine, arginine or salts thereof, betaine, N,N,-dimethyl-glycine, aspartic acid or salts thereof, glutamic acid or salts thereof; a polymer of an amino acid having a charged side group at physiological pH may be selected from polylysine, polyaspartic acid, polyglutamic acid, polyarginine, polyhistidine, polyornithine and salts thereof; and choline derivatives are selected from the group consisting of choline chloride, choline dihydrogen citrate, choline bitartrate, choline bicarbonate, tricholine citrate, choline ascorbate, choline borate, choline gluconate, choline phosphate, di(choline)sulphate and dicholine mucate.
US patent specification No. 4,917,685 discloses a delivery device designed to be implanted comprising growth hormone stabilized using the same stabilizers as mentioned in EP
303746.
Published European patent application No. 374,120 discloses a stabilized formulation comprising hGH and a polyol having three hydroxy groups. Glycerol and tris(hydroxymethyl)amino-methane are mentioned. Furthermore, the presence of histidine hydrochloride as a buffer together with the polyol is disclosed.

International Patent Publication No. WO 92/00998 discloses that crystals may be formed crystallizing growth hormone with zinc.

International Patent Publication No. W0 93/12811 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising asparagine.

CA 02226~23 l998-0l-08 W097/03692 PCT~K96/00293 International Patent Publication No. WO 93/12812 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising histi-dine. In such formulations the deamidation is reduced by 25-30% as compared to a corresponding formulation of growthhormone comprising phosphate buffer- Furthermore, it -is disclosed that crystals may be formed crystallizing growth hormone with zinc in the presence of histidine.

International Patent Publication No. W0 93/19776 discloses protein formulations comprising growth hormone comprising citrate as buffer substance being more stable than formula-tions comprising phosphate buffer. The formulations may also comprise amino acids such as glycine and alanine and/or man-nitol or other sugar alcohols and/or glycerol and/or othercarbohydrates and optionally a preservative such as benzyl alcohol.

International Patent Publication No. WO 94/03198 discloses a stable aqueous formulation cont~in;ng human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative.

Published European patent application No. 177,478 discloses a prolonged release composition comprising zinc and somatotropin in a continuous phase with a biocompatible oil.

Published European patent application No. 216,485 discloses a sustained-release composition comprising zinc and somatotropin in a vehicle comprising a vegetable oil and an adjuvant, especially beeswax, aluminum monostearate, - carnauba wax or paraffin.

Published European patent application No. 277,043 discloses recovering somatotropin from an aqueous solution by adding a salt of a transition metal and precipitation of an insoluble complex.
-CA 02226~23 1998-01-08 WO 97/03692 PCT/DK961'~ ~ 293 International Patent Publication No. WO 93/13792 discloses a delayed release implantable device comprising a somatotropin and zinc and optionally a basic side group cont~i n; ng amino acid solubilizing Zn-somatotropin, arginine, alanine, histidine and glutamic acid being mentioned as examples of amino acids.

International Patent Publication No. WO 92/17200 discloses stable growth hormone metal ion formulations in the form of dimers showing stability to denaturation. The formulations may comprise glycine and optionally additionally alanine, glutamine, asparagine, arginine or lysine, such amino acids being particularly advantageous when lyophilizing the formulation to create a sufficient mass to form a stable, dry caked formulation.

BRIEF DESCRIPTION OF THE INVENTION

It has now surprisingly been found that a formuIation of hu-man growth hormone with zinc and optionally lysine or cal-cium ions before preparation of the final formulation shows a very high stability against deamidation in aqueous solution and is furthermore readily dissolvable in aqueous solvents when lyophilized. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formula-tion.

The ph~r~ceutical formulations of the invention may be formulated for administration in any suitable way, e.g. by parenteral or oral administration or administration to a mucosal membrane, e.g. nasal ~m;n;stration. The pharmaceutical formulation may be presented in the form of a dose comprised in a vial or cartridge or any other suitable container such as a prefilled syringe or a pen device.

CA 02226~23 1998-01-08 W097/03692 PCT~K96/00293 Thus, the formulation of the inventlon may be in the form of a lyophilized powder to be reconstituted later using conven-tional vehicles such as dlstilled water or water for injec-tion or in the form of a solution comprising growth hormone.
Such vehicles may comprise conventional preservatives such as phenol, m-cresol and benzyl alcohol.

A preferred embodiment of the invention is in the form of a pharmaceutical formulation of human growth hormone pre-treated with zinc and optionally lysine or calcium ions and further comprising a carrier in the form of a buffered aque-ous solution of growth hormone. Such formulation is in a ready-to-use form and may be stored and shipped as an aque-ous solution without any considerable degradation.

A buffer to be used in a solution of pre-treated growth hor-mone may e.g. be histidine, citrate, tartrate or phosphate buffer. Preferably, the buffer is histidine buffer.
The pre-treatment solution is preferably adjusted to a value in the interval from about 2 to about 9, more preferred to pH from 6 to 8, especially to about 7-7.3.

For stability reasons the pH in the final formulation of pre-treated growth hormone is preferably adjusted to a value of about 2 to about 9, more preferred to a value of about 6 to about 8, especially to a value of about 6.0 to about 6.8.

In order to obtain the stabilizing effect of zinc and optionally lysine or calcium ions zinc is preferably added - in an amount of up to 2mM, preferably from about 1 to about 4 moles Zn per mol of growth hormone, preferably about 1 to 2 moles Zn per mole growth hormone, most preferred about 1 mol Zn per mol growth hormone.

CA 02226~23 l998-0l-08 Wos7/036s2 PCT~K96/00293 Zinc is preferably added in the form of a physiologically acceptable soluble salt such as the chloride.

Calcium ions when present are preferably added in the form of a physiologically acceptable soluble salt such as the chloride.

The pharmaceutical formulation of the invention may further-more comprise salts or sugar alcohols for adjusting the tonicity and optionally an excipient in order to facilitate the processing thereof, e.g. lyophilization and the rapid and complete dissolution of a lyophilized formulation when reconstituting the formulation before use.

An excipient may be selected from disaccharides such as lac-tose, trehalose, and sucrose, sugar alcohols such as sorbitol or mannitol, polysaccharides such as the polymers commercialized as Dextran~ products such as Dextran~ 40, Dextran~ 70 or Dextran~ 75, and Ficoll~ and polyvalent alcohols such as polyethylene glycol or polyvinyl alcohol or a combination of two or more of these.

In a further aspect the invention relates to a method of preparing a pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions wherein the growth hormone is dissolved in a solution comprising zinc and optionally lysine or calcium ions by dissolving zinc chloride in deionized water optio-nally cont~ining lysine or calcium ions, letting the solution stand for a while, adding the growth hormone and optionally adjusting the pH to from about 2 to about 9.

The pH may be adjusted by adding an acid which has no adverse effect on the growth hormone, preferably a physiologically acceptable acid e.g. a mineral acid such as hydrochloric acid, sulphuric acid or nitric acid or an organic acid such as acetic acid.

CA 02226~23 l998-0l-08 W097/03692 PCT~K96/00293 In an embodiment of the method of the invention, is added optionally salts and an excipient, whereafter the solution is filled into a container and lyophilized.
Still another aspect of the invention relates to the use of zinc and optionally lysine or calcium ions for pre-treatment of growth hormone for the formulation of a stabilized formu-lation of growth hormone.
In yet another aspect the invention relates to a method for treating a disorder affectable by growth hormone comprising administering a formulation which comprises a growth hormone pre-treated with zinc and optionally lysine or calcium ions.
In the present context "growth hormone" may be growth hormone from any origin such as avian, bovine, equine, human, ovine, porcine, salmon, trout or tuna growth hormone, preferably bovine, human or porcine growth hormone, human growth hormone being most preferred. The growth hormone used in accordance with the invention may be native growth hormone isolated from a natural source, e.g. by extracting pituitary glands in a conventional manner, or a growth hormone produced by recombinant techniques, e.g as described in E.B. Jensen and S. Carlsen in Biotech and Bioeng. 36, 1-11 (1990). The "growth hormone" may also be a truncated form of growth hormone wherein one or more amino acid residues has (have) been deleted; an analogue thereof wherein one or more amino acid residues in the native molecule has (have) been substituted by another amino acid residue, preferably a natural amino acid residue, as long as the substitution does not have any adverse effect such as antigenicity or reduced actioni or a derivative thereof, e.g having an N- or C-term; n~ 1 extension such as Met-hGH. The preferred growth hormone is hGH.

CA 02226s23 1998-0l-08 W097/03692 PCT~K96/00293 The term "dose" of growth hormone refers to that amount that provides therapeutic effect in an administration regimen.
The formulations hereof are prepared containing amounts of hGH at least about 0.1 mg/ml, preferably upwards of about 10 mg/ml, preferably from about 1 mg/ml to about 40 mg/ml, more preferably from about 1 mg/ml to about 25 mg/ml, e.g from 1 mg/ml to about 5 mg/ml, calculated on the ready-to-use formulation. For use of these compositions in administration to human beings suffering from hypopituitary dwarfism, for example, these formulations contain from about 0.1 mg/ml to about 10 mg/ml, corresponding to the currently contemplated dosage regimen for the intended treatment. The concentration range is not critical to the invention and may be varied by the physician supervising the administration.
Lysine to be used in accordance with the present invention is preferably the naturally occurring alpha amino acid. The lysine may be l or d lysine or a mixture thereof.

In the present context "high stability" is obtained when the formulation is more stable than the conventional formulation comprising phosphate buffer and preferably as stable as a corresponding formulation comprising histidine as stabilizer in which the deamidation of hGH is reduced by approximately 20% as compared with phosphate buffer as disclosed in WO
93/12812.

The solvent used in the method of the invention may be water, alcohols such as ethyl, n-propyl or isopropyl, butyl alcohol or mixtures thereof. The solvent may comprise a preservative such as phenol, m-cresol or benzyl alcohol.

CA 02226~23 l998-0l-08 W097/03692 PCT~K96/00293 The term "pre-treated" is used in the present context in connection with growth hormone formulations to designate a growth hormone which is treated with zinc and optionally lysine or calcium ions before the addition of or to the < 5 further components for preparation of a growth hormone for-mulation.

DETAILED DESCRIPTION OF THE INVENTION

10 The invention is explained more in detail in the below Exam-ples which illustrate the invention. They are not to be con-sidered as limiting the scope of the invention being defined by the appended claims.

EXPERIMENTAL PART

EX~MPLE

20 Reduction of the deamidation.

The rate of deamidation after different pre-treatments was examined at 37~C for hGH formulations containing 4 mg/ml hGH, O.18 mM ZnCl2, 3 mM histidine, 1.5~ benzyl alcohol, pH 6.8 as 25 compared to histidine and phosphate buffer at pH 6.8.

The hGH formulations were prepared by dissolving 24 mg hGH
in 2.5 ml of a) 2 mM CaCl22 + 0.36 mM ZnCl2, pH 7-7.3, b) 2 mM lysine + O.36 mM ZnCl2, pH 7-7.3 or c) O.36 mM ZnCl2, pH 7-7.3.
, After storage 1 h at 4~C (to allow Zn++ to complex with hGH) the preparations a)-c) were reformulated using a PD10 desalting column (Pharmacia) into 3 ml 6 mM histidine, 0.36 mM ZnCl2, 8 mg/ml hGH. Thereafter 3 ml 3% benzyl alcohol were added resulting in a final formulation of 4 mg/ml hGH, 3 mM

CA 02226~23 1998-01-08 W097/03692 PCT~K96/00293 histidine, 0.18 mM ZnCl2, 1.5~ benzyl alcohol, (pH adjusted to 6.8 adding HCl/NaOH).

As reference formulations were used a) 4mg/ml hGH, 3 mM
histidine, 0.18 mM ZnCl2 1.5% benzyl alcohol, pH 6.8; b) 4mg/ml hGH, 3 mM histidine, 1.5% benzyl alcohol, pH 6.8; and c) 4 mg/ml hGH, 3 mM Na2HPO4, 1.5% benzyl alcohol, pH 6.8.
The reference formulations were not pre-treated with Zn++.

The hGH formulations stated in the below table were stored at 37~C for 7 days, and analyzed for the content of deamidated hGH by IE-HPLC. The results appear from the below table CA 02226~23 1998-01-08 WO 97/03692 PCT/DK96/(~0293 Formulation pHstart /pI~end Content of Content of deamidated deamidated hGH forms as (%)# compared with histidi-ne (%) 3 mM histidine,0.18 mM 6.78/6.8~ 10.0 84 ZnCl2, 1.5% benzyl alcohol, pH 6.8.
Pre-treated in accor-dance with procedure a) 3 mM histidine,0.18 mM 6.75/6.83 11.3 88 ZnCl2, 1.5~ benzyl alcohol, pH 6.8.
Pre-treated in accor-dance with procedure b) 3 mM histidine,0.18 6.79/6.87 11.5 89 mM ZnClz, 1.5~
benzyl alcohol, pH
6.8.
Pre-treated in accordance with procedure c) 3 mM histidine,0.18 mM 6.84/6.92 12.8 99 ZnCl2, 1.5% benzyl alcohol, pH 6.8.
No pre-treatment.
3 mM histidine, 1.5% 6.84/6.92 12.9 100 benzyl alcohol, pH 6.8 3 mM Na2HPO4, 1.5% 6.83/6.86 15.9 123 benzyl alcohol, pH 6.8 #Desamido content corrected by 1% per 0.1 pH unit deviation from 6.8.

From the above table it appears that the deamidation rate of hGH is reduced to 84% relative to the histidine (68%
relative to the phosphate formulation) when the hGH solution ~ is treated with Zn++ in the presence of Ca++ or lysine prior to resalting into the final histidine formulation.

Claims (10)

1. A pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions.
2. A pharmaceutical formulation as claimed in claim 1 further comprising a carrier in the form of a buffered aqueous solution of growth hormone pre-treated with zinc and optionally lysine or calcium ions.
3. A pharmaceutical formulation as claimed in claim 1 or 2 wherein the pH is adjusted to a value in the interval from about 2 to about 9.
4. A pharmaceutical formulation as claimed in any of the preceding claims wherein the concentration of zinc is up to about 2 mM.
5. A pharmaceutical formulation as claimed in any of the preceding claims further comprising salts and/or saccharides and/or sugar alcohols.
6. A pharmaceutical formulation as claimed in any of claims 1-5 wherein the growth hormone is hGH.
7. A method of preparing a pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions wherein the growth hormone is dissolved in a solution comprising zinc and optionally lysine or calcium ions by dissolving zinc chloride in deionized water optionally containing lysine or calcium ions, letting the solution stand for a while, adding the growth hormone, optionally adding a preservative, and optionally adjusting the pH to from about 2 to about 9.
8. A method as claimed in claim 7, wherein is added optionally salts and/or sugar alcohols and an excipient, whereafter the solution is filled into a container and lyophilized.
9. Use of zinc and optionally lysine or calcium ions for pre-treatment of growth hormone for the formulation of a stabilized formulation of growth hormone.
10. A method for treating a disorder affectable by growth hormone deficiency, comprising administering the formulation of claim 1.
CA002226523A 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions Abandoned CA2226523A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14
US60/001,193 1995-07-14

Publications (1)

Publication Number Publication Date
CA2226523A1 true CA2226523A1 (en) 1997-02-06

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002226523A Abandoned CA2226523A1 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Country Status (14)

Country Link
EP (1) EP0839049A1 (en)
JP (1) JPH11509212A (en)
KR (1) KR19990028981A (en)
CN (1) CN1190897A (en)
AU (1) AU715997B2 (en)
BR (1) BR9609741A (en)
CA (1) CA2226523A1 (en)
CZ (1) CZ9498A3 (en)
HU (1) HUP9802287A3 (en)
IL (1) IL122583A0 (en)
NO (1) NO980155L (en)
PL (1) PL324379A1 (en)
WO (1) WO1997003692A1 (en)
ZA (1) ZA965368B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275422A1 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
DE69936382T3 (en) 1998-05-15 2011-07-07 Genentech, Inc., Calif. THERAPEUTIC USES OF IL-17 HOMOLOGOUS POLYPEPTIDE
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP2290081A3 (en) 1999-12-23 2012-08-01 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
CN1425066B (en) 2000-01-13 2010-05-26 杰南技术公司 Novel stra6 polypeptides
AU2001238540A1 (en) 2000-02-24 2001-09-03 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
CA2402191C (en) 2000-03-24 2012-03-13 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA03000073A (en) 2000-06-26 2003-09-25 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
ATE412009T1 (en) 2000-08-24 2008-11-15 Genentech Inc METHOD FOR INHIBITING IL-22 INDUCED PAP1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
CA2528343A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
SI1641822T1 (en) 2003-07-08 2013-08-30 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
CN1950397B (en) 2004-03-30 2012-05-16 Ns基因公司 Therapeutic use of a growth factor, NsG33
EP1814574A4 (en) 2004-10-27 2009-08-05 Univ Denver Adrenocorticotropic hormone analogs and related methods
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
PL2314623T3 (en) 2005-06-21 2012-11-30 Xoma Us Llc IL-1beta binding antibodies and fragments thereof
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
DE602006018746D1 (en) 2005-08-24 2011-01-20 Univ Rockefeller PLY-GBS MUTANT LYSINE
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
AU2006343279B2 (en) 2005-12-22 2012-03-29 Genentech, Inc. Recombinant production of heparin binding proteins
JP4682251B2 (en) 2006-02-02 2011-05-11 トリメリス,インコーポレーテッド HIV fusion inhibitor peptides with improved biological properties
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
EP2389946A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
AU2007238186B2 (en) 2006-04-10 2014-01-09 Genentech, Inc. Disheveled PDZ modulators
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2049148B1 (en) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
MX2009006709A (en) 2006-12-20 2009-07-02 Xoma Technology Ltd Methods for the treatment of il-1ã¿ related diseases.
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 Use of interleukin-22 in treating fatty liver
MX2010006823A (en) 2007-12-20 2010-09-30 Xoma Technology Ltd Methods for the treatment of gout.
KR101704832B1 (en) * 2008-08-15 2017-02-08 아이언우드 파마슈티컬스, 인코포레이티드 Linaclotide-containing formulations for oral administration
EP2331077A2 (en) * 2008-09-04 2011-06-15 Ironwood Pharmaceuticals, Inc. Stable forlulation comprising therapeutic polypeptides for oral administration
MX2012001660A (en) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration.
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
KR20120113265A (en) 2010-01-15 2012-10-12 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Use of vanadium compounds to accelerate bone healing
PL2536742T3 (en) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP5937059B2 (en) 2010-03-22 2016-06-22 ジェネンテック, インコーポレイテッド Compositions and methods useful for stabilizing protein-containing formulations
EP2566510A1 (en) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Compositions and methods useful for reducing the viscosity of protein-containing formulations
NZ605147A (en) 2010-06-24 2014-12-24 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
ES2919136T3 (en) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Stable formulations of linaclotide
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术(上海)有限公司 Application of interleukin-22 in curing virus hepatitis
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
WO2012045281A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
KR101687060B1 (en) 2010-10-08 2016-12-15 상하이 켁신 바이오테크 씨오., 엘티디. Moesin modulators and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
SG10201604488TA (en) * 2011-06-02 2016-07-28 Baxter Int Formulations Of Recombinant Furin
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
MY187874A (en) 2011-10-31 2021-10-26 Genentech Inc Antibody formulations
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US9688747B2 (en) 2013-03-15 2017-06-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP3022221B1 (en) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105792851B (en) 2013-09-13 2023-10-10 斯克利普斯研究所 Modified therapeutic agents and compositions thereof
CN105814083A (en) 2013-10-15 2016-07-27 加州生物医学研究所 Chimeric antigen receptor T cell switches and uses thereof
JP6734774B2 (en) 2013-10-15 2020-08-05 ザ スクリプス リサーチ インスティテュート Peptide chimeric antigen receptor T cell switch and uses thereof
CN104623639A (en) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Application of interleukin-22 dimer in preparation of drugs for treating pancreatitis
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
CN107921098A (en) 2015-06-17 2018-04-17 加州生物医学研究所 Therapeutic agent of modification and combinations thereof
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
US11174306B2 (en) 2016-10-19 2021-11-16 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
AR118536A1 (en) 2019-04-01 2021-10-20 Genentech Inc COMPOSITIONS AND METHODS TO STABILIZE FORMULATIONS CONTAINING PROTEIN
TW202120551A (en) 2019-08-12 2021-06-01 美商普瑞諾生物科技公司 Methods and compositions for promoting and potentiating t‐cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CA3217865A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
EP4333872A1 (en) 2021-05-06 2024-03-13 Hoba Therapeutics ApS Prevention and treatment of chemotherapy-induced neuropathic pain
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations

Also Published As

Publication number Publication date
NO980155D0 (en) 1998-01-13
JPH11509212A (en) 1999-08-17
ZA965368B (en) 1997-01-14
HUP9802287A2 (en) 1999-02-01
KR19990028981A (en) 1999-04-15
BR9609741A (en) 1999-03-16
NO980155L (en) 1998-01-13
CN1190897A (en) 1998-08-19
WO1997003692A1 (en) 1997-02-06
AU715997B2 (en) 2000-02-17
HUP9802287A3 (en) 2000-10-30
CZ9498A3 (en) 1998-06-17
AU6353496A (en) 1997-02-18
PL324379A1 (en) 1998-05-25
EP0839049A1 (en) 1998-05-06
IL122583A0 (en) 1998-06-15
MX9800358A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
AU715997B2 (en) A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions
US5705482A (en) Pharmaceutical formulation
CA2252535C (en) A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
US5851992A (en) Treatment of growth hormone deficiency
US5654278A (en) Composition and method comprising growth hormone and leucine
US8841252B2 (en) Pharmaceutical formulation
US5631225A (en) Pharmaceutical formulation
US5547696A (en) Pharmaceutical formulation
EP0785797B1 (en) A pharmaceutical formulation comprising a growth hormone and leucine
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5552385A (en) Pharmaceutical formulation
AU4329596A (en) A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
CA2226553A1 (en) A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue
US20030162711A1 (en) Pharmaceutical formulation
AU4329496A (en) A stabilized pharmaceutical formulation comprising a growth hormone and lys-x
MXPA98000358A (en) Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal
MXPA98000309A (en) Stabilized pharmaceutical formulation comprising a hormone of growth and a peptide that comprises at least one residue of basic amino acid and at least one waste of aminoacido ac

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20030630